This portfolio showcases startups that have emerged from UTHealth Houston innovations and collaborations. These companies represent the entrepreneurial spirit and translational impact of our research community—turning cutting-edge discoveries into real-world solutions that advance health and patient care.
Accumed Systems, Inc.
Commercializes innovative tools for interventional medicine. Recently, Accumed became a UTHealth Houston Porfolio company by licensing the technology pioneered by UTHealth Houston’s Drs. James Willerson and Ward Casscells in the area of thermal detection of vulnerable atherosclerotic plaque.
Alzeca Biosciences, LLC
Develops novel imaging agents for early diagnosis of neurodegenerative diseases, with a primary focus on Alzheimer's disease detection through MRI.
AusTech Pharmaceuticals LLC
Develops and commercializes novel drug formulations, with an emphasis on repurposing existing compounds for new therapeutic applications.
Cellvation, Inc.
A clinical-stage biopharmaceutical company developing novel cellular therapeutics for the treatment of traumatic brain injury. Cellvation is also developing CEVA-D, a novel bioreactor that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation. These technologies are based out of the labs of Drs. Charles S. Cox, Jr. and Brijesh Gill.
Coagulex, Inc.
Focused on the development, manufacture, and sale of hand-held MEMS based point of injury coagulation assessment tools. The devices, co-invented by UTHealth’s Dr. Brijesh Gill, Dr. Charles S Cox, and Kevin Aroom, potentially provide actionable results for therapeutic intervention within 120 seconds, without the need for pre-calibration, and with a limited blood sampling requirement (less than 50 microliters).
Decisio Health, Inc.
Commercializing a clinical decision support platform created by the team at UTHealth Houston’s Center for Translational Injury Research (CeTIR) led by Dr. John Holcomb. The platform hopes to improve clinical outcomes and reduce hospital costs by visually integrating clinical result and patient information in real-time while providing decision assist recommendations based on customizable clinician defined protocols.
EMIT Corporation
Emergency Medical Interventional Technologies Corporation is developing trauma care products based on innovative devices developed by UTHealth’s Drs. Charles Cox, Jr. and Brijesh Gill from the Departments of Pediatric Surgery and Surgery, respectively. EMIT’s first product includes a novel, patent-protected, portable fluid warmer to deliver therapeutic temperature management to patients experiencing hypothermia anywhere in the world and much sooner after injury.
Endothelix, Inc.
An early stage medical company, was awarded a $1 million grant from the State of Texas Emerging Technologies Fund for the development of its VENDYS™ system, for the measurement of vascular reactivity, and endothelial dysfunction. Recently VENDYS™ was approved by the FDA for commercial sale.
Immune-Onc Therapeutics, Inc.
A newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients, including technology developed in part in the laboratory of UTHealth Houston’s Dr. Zhiqiang An.
LifeBot, LLC
Designs advanced telemedicine and emergency medical technologies, including mobile health platforms for rapid response and remote care.
LifeCell
LIFC develops and markets products in the field of regenerative medicine for use in reconstructive surgical procedures. LIFC’s products include ALLODERM® regenerative tissue matrix, for plastic reconstruction. LIFC had an IPO in 1992, and in 2008, projected revenues are estimated at $233.0 million. LIFC recently announced its acquisition by Kinetics Concepts Inc. for $1.7 B.
NanoMedical Systems, Inc.
NMS is developing novel implantable nanochannel-based drug delivery systems developed by Dr. Mauro Ferrari and colleagues. Nano-channel chips allow for controlled drug release from subcutaneous reservoirs. NMS is pioneering personalized medicine by integrating semiconductor, biotechnology, MEMS/NEMS, and pharmaceuticals.
Neogenis Labs, Inc.
Created to develop novel formulations of nutritional supplements for daily cardiovascular health as well as enhanced exercise performance based on research developed by UTHealth Houston’s Dr. Nathan Bryan in the Institute of Molecular Medicine. Neogenis launched their first product in August of 2010.
Panamab, Inc.
A biotech company that focuses on new target identification and validation, and discovery and development of first-in-class and/or best-in-class monoclonal antibodies and companion diagnostics for the treatment of cancers and other serious diseases based on technology developed in part in the laboratory of UTHealth Houston’s Dr. Zhiqiang An.
PLx Pharma Inc.
Specializes in developing new formulations of non-steroidal anti-inflammatory agents (NSAIDs) pioneered by Dr. Lenard Lichtenberger. PLx completed four clinical trials with two lead products, and a third product recently received IND approval. PLx raised over $11 million, and has sponsored $4M in research to UTHealth Houston and UT Medical Branch.
SES
An innovative web-based disaster exercise technology that targets health care responders and other vital response sectors in areas where they have health related responsibilities, such as law enforcement, EMS, fire services, preparedness training in bioterror, mass casualty, natural disaster, and pandemic flu. SES webinars feature nationally known speakers dealing with topics pertinent to the disaster preparedness community to provide exercises and assessment needs.
TexTeach, LLC
Develops and markets products in the field of elder care based on research by UTHealth Houston’s Dr. Nancy Bergstrom and colleagues. TexTeach’s products include instructional videos titled “How to Predict and Prevent Pressure Sores” and “Elder Loving Care Oral Hygiene: Caregiver Training.
Volcano, Inc.
VOLC: NASDQ est. in 2001, specializes in the manufacture of intravascular ultrasound and other devices for use in the assessment of heart and vascular disease. Volcano had an Initial Public Offering (IPO) in June 2006, based, in part, on the value of technology pioneered by UTHealth Houston faculty Drs. James Willerson and Ward Casscells in the area of thermal detection of vulnerable atherosclerotic plaque. Volcano currently has over 500 employees with worldwide sales approaching $100 million.
Windmill Cardiovascular Systems, Inc.
WCS is commercializing a left ventricular assist device and a total artificial heart, in addition to other cardiovascular and non-biomedical devices. The WCS blood pump, TORVADTM, eliminates inlet and outlet valves while providing capability for control and synchronization with the native heart over a wide range of blood flows from near steady flow to pulsatile flow.
WNTrix, Inc.
A biotechnology company aiming to develop breakthrough therapeutics for cancer treatment. Its first program is based on the discovery of antibodies and their drug conjugates against a novel target by UTHealth Houston’s Dr. Q. Jim Liu. The target is abundantly expressed in cancer cells in substantial fractions of solid tumors and in tumor-associated immune cells. Its targeting may provide a novel treatment to patients with tumors expressing high levels of this target.
Zymo Pharmaceuticals, LLC
A biopharmaceutical company dedicated to developing innovative therapies targeting metabolic and genetic disorders, leveraging advanced drug delivery and molecular technologies.
